Chularat Hospital PCL (BKK:CHG) Research & Development: ฿0 Mil (TTM As of Mar. 2026)


BKK:CHG Chularat Hospital PCL BKK:CHG
83 GF Score
Price ฿1.60
GF Value ฿2.60
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Chularat Hospital PCL Research & Development?

Chularat Hospital PCL BKK:CHG +0.63% 83 Research & Development is ฿0 Mil as of Mar. 2026. GuruFocus rates BKK:CHG with a GF Score™ of 83/100 and a GF Value™ of ฿2.60 (Significantly Undervalued). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Chularat Hospital PCL's Research & Development for the three months ended in Mar. 2026 was ฿0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ฿0 Mil.

Chularat Hospital PCL  (BKK:CHG) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Chularat Hospital PCL Research & Development Related Terms

Chularat Hospital PCL Research & Development Historical Data

* Premium members only.

The historical data trend for Chularat Hospital PCL's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chularat Hospital PCL Research & Development Chart

Chularat Hospital PCL Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Chularat Hospital PCL Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BKK:CHG
83GF Score
Chularat Hospital PCL BKK:CHG
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chularat Hospital PCL Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ฿0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ฿0 Mil mean?
Chularat Hospital PCL (BKK:CHG) has a Research & Development of ฿0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Chularat Hospital PCL and its competitors.
Is Chularat Hospital PCL's Research & Development too high?
Chularat Hospital PCL's current Research & Development is ฿0 Mil. Overall, Chularat Hospital PCL has a GF Score™ of 83/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Chularat Hospital PCL's Research & Development compare to HCA and THC?
Chularat Hospital PCL's Research & Development of ฿0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Chularat Hospital PCL and its competitors. Chularat Hospital PCL's current Research & Development is ฿0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chularat Hospital PCL stock overvalued right now?
Based on GuruFocus' analysis, Chularat Hospital PCL (BKK:CHG) is currently considered Significantly Undervalued. The stock's GF Value™ is ฿2.60, compared to a current price of ฿1.60 — trading 38.5% below its estimated fair value. The current Research & Development is ฿0 Mil. Chularat Hospital PCL's overall GF Score™ is 83/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Chularat Hospital PCL (BKK:CHG), the current Research & Development is ฿0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Chularat Hospital PCL (BKK:CHG) Overvalued in 2026?

Based on GuruFocus' analysis, Chularat Hospital PCL stock appears to be undervalued. The current stock price of ฿1.60 is trading 38.5% below its estimated GF Value™ of ฿2.60. GuruFocus considers Chularat Hospital PCL to be Significantly Undervalued.

Key valuation signals for BKK:CHG:

  • Research & Development: ฿0 Mil
  • GF Value™: ฿2.60 vs. price of ฿1.60 (38.5% below fair value)
  • GF Score™: 83/100 with 4 warning signs

No single metric tells the full story. See the BKK:CHG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Chularat Hospital PCL Business Description

Address 88/8-9, Teparak Km. 15 Road, Tambol Bangpla, Amphur Bangplee, Samut Prakarn, THA, 10540
Chularat Hospital PCL operates hospitals and clinics in Thailand. The company operates through several branches of clinics and hospitals. The Group operates a private hospital business which is one business segment. It has only one geographical segment as the business operates only in Thailand.
83GF Score

Get the complete analysis for BKK:CHG

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

฿1.60
Price
฿2.60
GF Value